FR13C0045I2 - Vaccins chimeres inactives et leurs procedes d'utilisation - Google Patents

Vaccins chimeres inactives et leurs procedes d'utilisation

Info

Publication number
FR13C0045I2
FR13C0045I2 FR13C0045C FR13C0045C FR13C0045I2 FR 13C0045 I2 FR13C0045 I2 FR 13C0045I2 FR 13C0045 C FR13C0045 C FR 13C0045C FR 13C0045 C FR13C0045 C FR 13C0045C FR 13C0045 I2 FR13C0045 I2 FR 13C0045I2
Authority
FR
France
Prior art keywords
chimeral
vaccines
inactive
methods
inactive chimeral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0045C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of FR13C0045I1 publication Critical patent/FR13C0045I1/fr
Application granted granted Critical
Publication of FR13C0045I2 publication Critical patent/FR13C0045I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR13C0045C 2005-06-24 2013-07-24 Vaccins chimeres inactives et leurs procedes d'utilisation Active FR13C0045I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69362905P 2005-06-24 2005-06-24
PCT/US2006/024584 WO2007002470A2 (fr) 2005-06-24 2006-06-23 Vaccins chimeres inactives et leurs procedes d'utilisation

Publications (2)

Publication Number Publication Date
FR13C0045I1 FR13C0045I1 (fr) 2013-08-30
FR13C0045I2 true FR13C0045I2 (fr) 2014-05-16

Family

ID=37595900

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0045C Active FR13C0045I2 (fr) 2005-06-24 2013-07-24 Vaccins chimeres inactives et leurs procedes d'utilisation

Country Status (13)

Country Link
US (3) US8048429B2 (fr)
EP (1) EP1896069B1 (fr)
JP (1) JP5193856B2 (fr)
CN (1) CN101222936A (fr)
AU (1) AU2006261943B2 (fr)
BR (1) BRPI0611581B1 (fr)
CA (1) CA2612047C (fr)
FR (1) FR13C0045I2 (fr)
MX (1) MX2007016083A (fr)
NZ (1) NZ564375A (fr)
RU (1) RU2436591C2 (fr)
WO (1) WO2007002470A2 (fr)
ZA (1) ZA200710974B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
AU2009287449B2 (en) * 2008-08-29 2015-04-30 Boehringer Ingelheim Animal Health USA Inc. West nile virus vaccine
WO2010058236A1 (fr) * 2008-11-19 2010-05-27 Laboratorio Avi-Mex, S.A. De C.V. Vaccin recombinant à vecteur viral inactivé
WO2012065105A2 (fr) * 2010-11-12 2012-05-18 Thomas Monath Vaccins contre des flavivirus chimériques
BR112013023354B1 (pt) 2011-03-14 2022-02-15 Boehringer Ingelheim Animal Health Usa Inc Composição imunogênica compreendendo cepas de vírus da rinite equina a (erav) e seu método de produção
KR101567576B1 (ko) 2012-05-22 2015-11-10 올릭스 주식회사 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도
JP2016523251A (ja) 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
CN103352029A (zh) * 2013-07-29 2013-10-16 中国人民解放军军事医学科学院微生物流行病研究所 一种乙脑/森林脑炎嵌合病毒及其应用
ES2981476T3 (es) 2014-12-22 2024-10-09 Merck Sharp & Dohme Llc Composiciones de vacunas contra el virus del dengue y métodos de uso de las mismas
JP2015120709A (ja) * 2015-01-09 2015-07-02 ラボラトリオ アヴィメキシコ エスエー ディーイー シーヴィーＬａｂｏｒａｔｏｒｉｏ Ａｖｉ−Ｍｅｘ，Ｓ．Ａ． Ｄｅ Ｃ．Ｖ． 遺伝子組み換え不活性化ウィルスベクターワクチン
JP7027311B2 (ja) 2015-11-16 2022-03-01 オリックス ファーマシューティカルズ，インコーポレーテッド ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療
JP6944942B2 (ja) 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ，インコーポレーテッド ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
CN108779464B (zh) 2016-02-02 2022-05-17 奥利克斯医药有限公司 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病
JP7049262B2 (ja) 2016-04-11 2022-04-06 オリックス ファーマシューティカルズ，インコーポレーテッド 結合組織成長因子を標的とするｒｎａ複合体を用いた特発性肺胞線維症の治療
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
EP3580339A4 (fr) 2017-02-10 2020-12-23 Research & Business Foundation Sungkyunkwan University Arn double brin long pour interférence arn
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
WO2019112921A1 (fr) 2017-12-07 2019-06-13 Merck Sharp & Dohme Corp. Formulations de compositions de vaccin contre le virus de la dengue
WO2024102703A2 (fr) * 2022-11-07 2024-05-16 The Regents Of The University Of California Système de distribution de gènes basé sur zikv

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US104008A (en) * 1870-06-07 Improvement in producing mosaics upon marble
US255127A (en) * 1882-03-21 Rotary study-table or book-case
US241191A (en) * 1881-05-10 Half to augustus g
US223979A (en) * 1880-02-03 Henry w
US37848A (en) * 1863-03-10 Improved composition for lining oil-barrels
US163804A (en) * 1875-05-25 Improvement in laced boots and shoes
US31641A (en) * 1861-03-05 Improvement in potato-diggers
US22849A (en) * 1859-02-08 Henry j
US91595A (en) * 1869-06-22 Improvement in seed-planters
US52818A (en) * 1866-02-27 Improvement in metallic cartridges
US6676936B1 (en) * 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
EP1018556B1 (fr) * 1991-09-19 2005-11-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES Flavivirus chimériques et/ou flavivirus à croissance limitée
DE19521705C2 (de) * 1995-06-14 1997-10-09 Immuno Ag Immunogenes Konstrukt, Verfahren zu dessen Herstellung und Verwendung als Vakzine
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
AT410634B (de) * 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
US20050031641A1 (en) * 2001-04-06 2005-02-10 Loosmore Sheena May Recombinant vaccine against West Nile Virus
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US6682883B1 (en) * 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
HU228690B1 (en) * 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
KR101131579B1 (ko) * 2001-10-19 2012-03-30 사노피 파스테르 바이오로직스 씨오 동물의 플라비바이러스 감염 예방 및 치료 방법
US7276353B2 (en) * 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
DE60330795D1 (de) * 2002-11-08 2010-02-11 Crucell Holland Bv Impfstoff gegen west nile virus
US20050287170A1 (en) 2002-12-11 2005-12-29 Hawaii Biotech, Inc. Subunit vaccine against West Nile viral infection
CA2605924A1 (fr) 2005-04-24 2006-11-02 Acambis Inc. Vaccins a flavivirus recombinants

Also Published As

Publication number Publication date
US8133712B2 (en) 2012-03-13
EP1896069A4 (fr) 2010-01-27
BRPI0611581B1 (pt) 2021-08-03
EP1896069A2 (fr) 2008-03-12
RU2008102654A (ru) 2009-07-27
BRPI0611581A2 (pt) 2011-02-22
JP2008546416A (ja) 2008-12-25
RU2436591C2 (ru) 2011-12-20
US8048429B2 (en) 2011-11-01
FR13C0045I1 (fr) 2013-08-30
NZ564375A (en) 2010-02-26
ZA200710974B (en) 2008-10-29
US20090246223A1 (en) 2009-10-01
EP1896069B1 (fr) 2013-03-13
US20110212126A1 (en) 2011-09-01
US20070009548A1 (en) 2007-01-11
WO2007002470A3 (fr) 2007-11-01
CN101222936A (zh) 2008-07-16
AU2006261943B2 (en) 2010-12-02
CA2612047C (fr) 2015-05-12
WO2007002470A2 (fr) 2007-01-04
AU2006261943A1 (en) 2007-01-04
CA2612047A1 (fr) 2007-01-04
JP5193856B2 (ja) 2013-05-08
MX2007016083A (es) 2008-03-10

Similar Documents

Publication Publication Date Title
FR13C0045I2 (fr) Vaccins chimeres inactives et leurs procedes d'utilisation
EP2049559A4 (fr) Vaccins améliorés et leurs procédés d'utilisation
FR20C1033I1 (fr) Anticorps anti-cd79b, immuno-conjugues et procedes d'utilisation
EP1937268A4 (fr) Analogues d'indenoisoquinolinone et leurs procedes d'utilisation
EP1855833A4 (fr) Plasmas et procedes d'utilisation
MA30684B1 (fr) Anticorps anti-mn et leurs procedes d'utilisation.
EP1812102A4 (fr) Endoprothese occlusale et procedes d'utilisation associes
EP1706791A4 (fr) Compositions de photoresines et leurs procedes d'utilisation
EP1996020A4 (fr) Composes puriques et leurs procedes d'utilisation
EP1835915A4 (fr) Formulations de modificateur de reaction immunitaire et procedes associes
EP1740197A4 (fr) Preparation therapeutique a base d'enzymes et ses utilisations
EP1729768A4 (fr) Formulations modificatrices de reponse immunitaire et procedes correspondants
EP2083734A4 (fr) Marqueurs d'electrodes et leurs procedes d'utilisation
EP1879626A4 (fr) Polymeres amphiphiles et leurs procedes d'utilisation
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
EP2212432A4 (fr) Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
EP1957434A4 (fr) Tensioactifs permutables de maniere reversible et leurs procedes d'utilisation
EP2373679A4 (fr) Mini peptides d'hépcidine et leurs procédés d'utilisation
EP1940787A4 (fr) Nouveaux inhibiteurs de l'ido et leurs procedes d'utilisation
EP1943507A4 (fr) Detecteur de nox et procedes d'utilisation associes
EP2086583A4 (fr) Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
EP1951050A4 (fr) Compositions therapeutiques et procedes
EP2040541A4 (fr) Adjuvants et procédés d'utilisation
EP1874731A4 (fr) Analogues de quinobenzoxazines et procedes d'utilisation de ceux-ci
EP2126076A4 (fr) Protéines dérivées des toiles d' araignées néphilengys cruentata avicularia juruensis et parawixia bistriata